Ezetimibe Improves Endothelial Function and Inhibits Rho-Kinase Activity Associated With Inhibition of Cholesterol Absorption in Humans

Nochioka, Kotaro; Tanaka, Sanae; Miura, Masanobu; Zhulanqiqige, Do e.; Shiba, Nobuyuki; Shimokawa, Hiroaki

doi:10.1253/circj.cj-12-0331

Cited by 28 publications

(17 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many studies reported that ezetimibe improves vascular endothelial dysfunction [65][66][67][68] , although whether the effect was as good as 69) , superior to 70) , or weaker than 71,72) the effect of statins is controversial. However, the inhibitory effect of simvastatin on SNA was not observed with ezetimibe 17) .…”

Section: -3 Ezetimibementioning

confidence: 99%

Do antilipidemic agents reduce blood pressure?

2018

View full text Add to dashboard Cite

Abstract:Currently, the prevalence of hypertension (HT), diabetes mellitus (DM), and hyperlipidemia (HL) is high, and these diseases are important risk factors for cardiovascular disease (CVD). Furthermore, patients with CVD often have more than one of these diseases. Generally, patients take multiple drugs for each disease. Therefore, clinicians must pay attention to drug interactions. Although HT, DM, and HL are different diseases, they share some of the same pathophysiological mechanisms and ultimately lead to the same cardiovascular events.Currently, most patients with CVD are treated with 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins), and various beneficial pleiotropic effects of statins have been reported since the 1990s.In this review, we evaluate the additional effects of antihyperlipidemic agents on blood pressure (BP).

show abstract

Section: -3 Ezetimibementioning

confidence: 99%

Do antilipidemic agents reduce blood pressure?

2018

View full text Add to dashboard Cite

show abstract

“…In this issue of the Journal, a critical hint on how to use ezetimibe has been suggested by Nochioka et al 8 It is quite noteworthy for clinical benefit to reveal that ezetimibe could inhibit Rho-kinase activity and increase endothelial function even in healthy subjects. Indeed, inhibition of Rho-kinase and improvement of endothelial function could subsequently lead to an improvement in cardiovascular prognosis.…”

Section: Article P 2023mentioning

confidence: 99%

“…8 So far, Rho-kinase has been shown to be a key negative regulator of endothelial function and clinically involved in the pathogenesis of cardiovascular diseases such as hypertension, pulmonary hypertension, HF, stroke, and angina. 2 Accordingly, Rho-kinase has recently been considered as a novel therapeutic target of atherosclerosis.…”

Section: Article P 2023mentioning

confidence: 99%

“…In contrast, Nochioka et al report that statins could not augment endothelial function, but that ezetimibe could in healthy subjects. 8 This discrepancy could be, in part, explained by the pathway to activate Rho-kinase. Indeed, statins have been reported to suppress Rho-kinase activity via inhibition of RhoA.…”

Section: Article P 2023mentioning

confidence: 99%

“…8 In particular, the view that the inhibition of the Rho-kinase pathway by ezetimibe is different from that by statins is attractive for finding a novel therapeutic target of atherosclerosis-related diseases. Only healthy volunteers have been investigated in this study.…”

Section: Article P 2023mentioning

confidence: 99%

See 2 more Smart Citations

How to Use Ezetimibe as an Anti-Atherogenic Agent via Inhibition of Rho-Kinase

Noma

Higashi

2012

Circ J

View full text Add to dashboard Cite

RhoA/mDia-1/profilin-1 signaling targets microvascular endothelial dysfunction in diabetic retinopathy

Chen

et al. 2015

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

This review focuses on the RhoA/mDia-1/profilin-1 signaling pathway that specifically triggers endothelial dysfunction in diabetic patients. Recently, RhoA and profilin-1 signaling has attracted a great deal of attention in the context of diabetes-related research. However, the precise molecular mechanism by which the RhoA/mDia-1/profilin-1 pathway is involved in progression of microvascular endothelial dysfunction (MVED) during DR has not been determined. This review briefly describes each feature of the cascade before exploring the most recent findings on how the pathway may trigger endothelial dysfunction in DR. When the underlying mechanisms are understood, novel therapies seeking to restore the endothelial homeostasis comprised in DR will become possible.

show abstract

Ezetimibe Improves Endothelial Function and Inhibits Rho-Kinase Activity Associated With Inhibition of Cholesterol Absorption in Humans

Cited by 28 publications

References 28 publications

Do antilipidemic agents reduce blood pressure?

Do antilipidemic agents reduce blood pressure?

How to Use Ezetimibe as an Anti-Atherogenic Agent via Inhibition of Rho-Kinase

RhoA/mDia-1/profilin-1 signaling targets microvascular endothelial dysfunction in diabetic retinopathy

Contact Info

Product

Resources

About